Pinned Tweet
Everything pointing to this being not just a Fabry deal for $SGMO but much l, much more. Wouldn’t be surprised if both HemoA and Fabry go to the same partner. Maybe even open deal for future GTs using the same AAV+Promoter. Beaucoup bucks coming our way.
Starting to feel bad about the long-term holders of $SGMO that recently cut bait and sold. This has the hallmarks of the start of a big run.
1
12
1,022
Ptosis humor is the best humor. #ophthalmology
83
Bullish. That’s just what prospective partners want to hear.
$SGMO In October, held a meeting with #FDA to discuss the proposed efficacy and safety data package where, in the meeting minutes, among other things, the FDA #reiterated its October 2024 agreement to use eGFR slope as an endpoint to support an #accelerated #approval pathway👍
1
7
974
Max Power retweeted
$SGMO In October, held a meeting with #FDA to discuss the proposed efficacy and safety data package where, in the meeting minutes, among other things, the FDA #reiterated its October 2024 agreement to use eGFR slope as an endpoint to support an #accelerated #approval pathway👍
My theory for the past couple months is the following:
1) multiple bidders for Fabry based on exceptional data
2) SM trying to bundle package of Fabry+HemoA+other GT targets, but this is less appealing based on HemoA durability questions. GT is no longer core to $SGMO
I just wish someone who has kicked the tires on $SGMO #Fabry data would come out and say: here’s why it isn’t interesting. I can accept defeat on trial failure. But the company’s representations vs the inability to close a deal is truly mind boggling. @sandymacrae23 why nothing?
3) potential of Fabry is keeping bidders at the table SM is trying to extract max value for the entire $SGMO gene therapy pipeline engine. Lots of potential targets (e.g. PKU, others) that are available and could work with proven vector and
strong promoter.
3
784
I expect Sandy to get out in front of this question about FDA temperature on Fabry early approval. Hopefully we can trust his view on an increasingly mercurial agency.
I personally wouldn’t say “don’t worry,” because concern is fair — what’s troubling here isn’t Sangamo’s data, it’s the FDA’s inconsistency. Slowing down a first-in-class gene therapy for a fatal disease is frustrating, but it doesn’t directly translate to Fabry.
1) The FDA hasn’t actually rejected anything.
So far, they’ve only asked for clarification. It could easily be a pre-emptive move to control the narrative or manage expectations early — smart move -> check the attached post
teapawt.net/soeren_berlin/status/1…
2) $QURE and $SGMO are at very different stages.
Sangamo’s ST-920 is ahead of UniQure’s AMT-191:
- ST-920 patients have much longer follow-up data — over a year on average, some nearing 5 years.
- UniQure is still in early-stage cohort testing.
- ST-920 already has patients who successfully discontinued ERT (enzyme replacement therapy); AMT-191 hasn’t reached that stage.
- The FDA has already interpreted ST-920’s interim endpoint (eGFR slope), giving Sangamo regulatory clarity. AMT-191, while orphan-designated, doesn’t yet have comparable guidance.
- ST-920 shows solid efficacy across enzyme activity, biomarkers, and kidney function in a larger patient group; AMT-191’s data are still early.
3) Fabry and HD are totally different cases.
Fabry has a validated shortcut — the FDA already accepts GL-3 / Lyso-Gb3 and renal data as surrogates for accelerated approval.
HD has none — no biomarker “reasonably likely to predict” benefit. That forces the FDA to rely on long, slow clinical outcomes.
Think of it like crossing the street at night: the light’s red but there’s no car in sight. You could safely cross, but the FDA insists on waiting for green.
4) Endpoint interpretability.
Fabry biomarkers move fast and clearly. HD endpoints are slow, noisy, and hard to interpret — making accelerated approval much riskier statistically.
5) Precedent matters.
The FDA granted Fabrazyme accelerated approval in 2003 using these same surrogates — and has applied that model ever since. There’s no similar precedent for HD.
TL;DR: The $QURE situation is frustrating but not a read-through for Sangamo. Fabry has clear biomarkers, established precedent, longer data, and demonstrated efficacy — HD doesn’t.
Still, since most investors don’t differentiate between programs, it’s creating unnecessary short-term tension. So political fear is legitimate, data based fear isn’t.
1
114
$SGMO early morning earnings call means they are announcing a deal before the market opens.
Load the boat!!
1
12
1,078
How is this even possible? 12 weeks! $SGMO
BOOOM: HUGE $SGMO Pain trial update:
Its now a #Phase2
Data not 52 but 12 !!! weeks
clinicaltrials.gov/study/NCT…
$SGMO must be getting really creative in finding ways to keep the lights on. Where is the deal Sandy!
2
10
2,199
BREAKING $SGMO Pain trial just #started recruiting
(means they #got the #funding to go on)
clinicaltrials.gov/study/NCT…
now we wait for the big PR ....
$SGMO I got a feeling Sandy is going to have a big announcement this week. Combined with a TACO Monday will be a fun week!
14
1,190
$SGMO — think we’re in the endgame now.
‘Soon’ is coming and I am looking forward to it.
I’m aware of at least three different people (including myself) who regularly exchange with Sangamo IR (Louise) or Sandy — all sent messages between last Thursday and Monday, and none have received a reply or reaction so far.
Seems like it’s busy busy days…
Might be coincidence, but that’s a first.
2
18
2,031
Max Power retweeted
$SGMO #Tregs
- STEADFAST study marks a true breakthrough
- Outstanding safety profile
- Very promising early efficacy signals
- immunosuppression tapering was achieved
This pioneering approach has the potential to redefine transplantation management...
#nobelprice
That’s a huge buy signal on $QURE. @CramerTracker












